Viking Therapeutics Gains Momentum in Competitive Weight-Loss Drug Arena

Novo Nordisk's clinical setback elevates Viking's VK2735 in obesity drug race. Viking holds $706M cash, plans Phase 3 oral trial for 2026 after stock surges 11%.

A recent shift in the competitive landscape for obesity treatments has provided a notable boost to Viking Therapeutics. The catalyst was disappointing clinical trial data from Novo Nordisk, which effectively reset expectations for efficacy in this crucial market. This development appears to play directly into the strengths of Viking's drug candidate, VK2735.

Clinical Setback for a Rival Reshapes Expectations

Novo Nordisk's REDEFINE-4 study failed to achieve its primary objective. The investigational therapy CagriSema did not demonstrate non-inferiority to Eli Lilly's Tirzepatid (marketed as Zepbound and Mounjaro) in weight reduction. In the 84-week trial involving 809 participants, weight loss averaged 20.2% for CagriSema, compared to 23.6% for Tirzepatid.

The message for the sector is clear: the class of GLP-1/GIP dual agonists, which includes both Tirzepatid and Viking's VK2735, has reaffirmed its position as highly effective. Following the data release, Novo Nordisk's shares declined to a 52-week low.

Financial and Development Position

Viking Therapeutics ended the fourth quarter of 2025 with a robust cash position of $706 million. Its research and development expenditures rose significantly to $153.5 million for Q4 (up from $31.0 million in the prior-year period) and totaled $345.0 million for the full year 2025 (compared to $101.6 million in 2024). The company reported a quarterly loss per share of -$1.38, which was wider than the consensus estimate of -$0.89. Viking continues to operate without revenue.

The next major catalysts for the company are the planned initiation of a Phase 3 trial for the oral formulation in the third quarter of 2026, along with data from a maintenance dose study, also expected in Q3 2026.

Stock Responds Positively to Sector Dynamics

Viking's equity enjoyed substantial gains on Monday. At the time of reporting, the stock was up 10.91% to $34.41; it traded between $31.92 and $35.73 during the session before closing at $34.21. Trading volume reached 3.66 million shares, exceeding the average of 3.29 million.

Commenting on the sector outlook, William Blair analyst Andy Hsieh noted that GLP-1/GIP dual agonists are likely to maintain a leading role in the U.S. market due to their favorable efficacy and tolerability profile. He identified VK2735, along with Kailera's Riputapatid and Roche's CT-388, as Phase 3 dual agonists with competitive potential.

Viking's VK2735 Program: A Dual-Pronged Approach

Viking is developing VK2735 in both injectable and oral tablet forms. Currently, no other competitor with a dual or triple agonist candidate is advancing both delivery methods in parallel.

The subcutaneous Phase 3 program, named VANQUISH, includes two pivotal studies:
* VANQUISH-1, involving approximately 4,650 adults with obesity, completed enrollment ahead of schedule.
* VANQUISH-2, with around 1,100 adults with type 2 diabetes, was recently near full recruitment.

For the oral version of VK2735, the company plans to commence Phase 3 trials in the third quarter of 2026, following an End-of-Phase 2 meeting with the FDA scheduled for December 2025. Additionally, an exploratory maintenance dose study with about 180 participants is already fully enrolled, with data anticipated also in Q3 2026.